Stratus Medical has secured $10.0 million in funding from investors, marking a significant step in its mission to improve clinical outcomes for chronic pain patients. This capital infusion will support the company's continued efforts in advancing radiofrequency (RF) technology for pain treatment. Stratus Medical, which has been recognized for innovation, revenue growth, and business performance by organizations such as Deloitte Technology Fast 500 and Pepperdine Most Fundable Companies, focuses on developing solutions that offer effective and efficient pain relief.
The company's flagship product, the Nimbus RF Multitined Expandable Electrode, is central to its offerings. Used in conjunction with an RF Generator and Probe, Nimbus is designed for radiofrequency heat lesion procedures to treat pain. This technology creates a large volume and optimally shaped lesion, aiming to provide faster procedure times, lower costs, and reproducible, durable pain relief for patients. The Nimbus system has received FDA clearance (Class II) and CE marking (Class IIb) and holds over 40 issued patents. It has been utilized in more than 300,000 patient treatments across various countries, including the United States, Australia, Italy, Spain, Brazil, Canada, and the United Kingdom.
The newly raised capital is expected to fuel Stratus Medical's growth initiatives, including expanding its market reach and supporting ongoing product development projects. The company also markets complementary technologies such as Vesta and Nimbus Disposable Probe. This investment underscores confidence in Stratus Medical's technology and its potential to further impact chronic pain management globally. Stratus Medical plans to leverage these funds to scale its operations, enhance its product portfolio, and continue its commitment to advancing RF technology for the treatment of pain, ultimately aiming to reach more patients in need.
